You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 24, 2025

Details for Patent: 11,253,472


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,253,472 protect, and when does it expire?

Patent 11,253,472 protects SYNDROS and is included in one NDA.

Summary for Patent: 11,253,472
Title:Oral cannabinoid formulations
Abstract: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.
Inventor(s): Goskonda; Venkat R. (Phoenix, AZ), Chavan; Ashok (Chandler, AZ), Kokate; Amit (Englewood, NJ), Gill; Howard (Scottsdale, AZ)
Assignee: Benuvia Therapeutics LLC (Chandler, AZ)
Application Number:16/282,817
Patent Claim Types:
see list of patent claims
Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,253,472: A Comprehensive Analysis

Introduction

Patent 11,253,472, like any other patent, is a complex document that outlines the scope and claims of an invention. To fully grasp its implications, it is crucial to delve into the patent's specifics, the broader patent landscape, and recent updates in patent law.

Patent Basics

What is a Patent?

A patent is a form of intellectual property that grants the inventor exclusive rights to make, use, and sell the invention for a specified period, typically 20 years from the filing date[2].

Key Components of a Patent

  • Claims: These are the most critical part of a patent, defining the scope of the invention and what is protected.
  • Description: This section provides a detailed explanation of the invention, including how it works and its various embodiments.
  • Drawings: Visual representations that help illustrate the invention.

The 2024 USPTO Guidance Update on AI Patents

Recent updates from the USPTO, effective July 17, 2024, have significant implications for patents involving AI technology. This guidance aims to clarify the process for determining the patent eligibility of AI-related inventions.

Evaluating Subject Matter Eligibility

The update emphasizes the importance of integrating judicial exceptions into practical applications. For a claim to be patent-eligible, it must impose meaningful limits on the exception, transforming the abstract idea into a concrete technological improvement[1].

AI-Assisted Inventions

The guidance makes it clear that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Determining Inventorship

Inventorship is a critical aspect of patent law, and incorrect identification can lead to unenforceable patents.

Conception and Reduction to Practice

In the United States, invention involves two steps: conception of the idea and reduction to practice. Conception is complete when the idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation[2].

True and Only Inventors

The "true and only" inventors must be listed in the patent application. Errors in inventorship can be corrected, but deceptive intent can render the patent unenforceable[2].

Patent Claims Analysis

Structure and Dependency

Patent claims can be analyzed using datasets like the USPTO's Patent Claims Research Dataset, which provides detailed information on claims from US patents and applications. This dataset helps in understanding the dependency relationships between claims and the scope of the patent[3].

Example Analysis

For instance, in the 2024 USPTO guidance, Example 48 illustrates how claims can be crafted to meet patent eligibility criteria. Claim 2 in this example specifies the use of separated audio components in a speech recognition system, adding a practical application that makes the claim patent-eligible. This contrasts with Claim 1, which involves routine data processing steps and is considered ineligible[1].

Patent Landscape and Trends

Historical Data

The USPTO's Patent Claims Research Dataset provides insights into patent trends from 1976 to 2014. This data can help in understanding the evolution of patent claims and the scope of patents over time[3].

Recent Case Law

Recent cases, such as those heard by the Court of Appeals for the Federal Circuit, continue to shape the patent landscape. These cases often address issues like obviousness, double patenting, and the impact of terminal disclaimers on patent terms[4].

Small Claims Patent Court

There is ongoing discussion about the feasibility of a small claims patent court, which could simplify and reduce the costs associated with patent litigation. The Administrative Conference of the United States (ACUS) has conducted studies and gathered public comments on this topic, highlighting the need for a more accessible and efficient system for resolving patent disputes[5].

Key Takeaways for Patent 11,253,472

  • Claims Analysis: The patent's claims must be carefully evaluated to ensure they integrate judicial exceptions into practical applications, as per the 2024 USPTO guidance.
  • Inventorship: Correct identification of the true and only inventors is crucial to avoid issues with patent enforceability.
  • Patent Scope: Understanding the dependency relationships between claims and the broader patent landscape can help in assessing the patent's scope and potential impact.
  • AI Involvement: If the invention involves AI, the method of development does not affect subject matter eligibility, but the claimed invention must still meet the criteria for patent eligibility.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated equally with other technologies[1].

How is inventorship determined in US patent law?

Inventorship is determined by identifying those who conceived the idea of the patent claims. Conception is complete when the idea is sufficiently definite and permanent to permit reduction to practice without undue experimentation[2].

What is the purpose of the USPTO's Patent Claims Research Dataset?

The dataset provides detailed information on claims from US patents and applications, helping in understanding the structure and dependency relationships between claims and the scope of patents over time[3].

Why is there a discussion about a small claims patent court?

The discussion aims to explore the feasibility of a more accessible and efficient system for resolving patent disputes, potentially reducing costs and simplifying the litigation process[5].

How do recent case laws impact the patent landscape?

Recent cases shape the interpretation of patent laws, addressing issues like obviousness, double patenting, and the impact of terminal disclaimers, thereby influencing how patents are granted and enforced[4].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Determining Inventorship for US Patent Applications - Oregon State University
  3. Patent Claims Research Dataset - USPTO
  4. In re Cellect - United States Court of Appeals for the Federal Circuit
  5. U.S. Patent Small Claims Court - Administrative Conference of the United States (ACUS)

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,253,472

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Benuvia Operations SYNDROS dronabinol SOLUTION;ORAL 205525-001 Mar 23, 2017 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.